← FDA DRUG APPROVALS

FDA NDA · NDA215431

SYMBRAVO

meloxicam, rizatriptan

Sponsor: AXSOME

APPLICATION
NDA215431
TYPE
NDA
ORIGINAL APPROVAL
2025-01-30
LATEST ACTION
2025-01-30
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SYMBRAVO · ReferencePrescription
MELOXICAM 20MG, RIZATRIPTAN BENZOATE EQ 10MG BASE · TABLET · ORAL

Approval history

2025-01-30Type 4 - New Combination · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →